Pedro Perez: Are We Measuring the Right Outcomes in VTE?
Pedro Perez, Senior Vascular Consultant at Argon Medical Devices, Inc., shared a post on LinkedIn:
”Are We Measuring the Right Outcomes in VTE?
In VTE, we often talk about technical success:
- Did we remove the clot?
- Did flow improve?
- Did the case go smoothly?
But the bigger question is… does that actually define success for the patient?
Because what matters long-term isn’t just what happens in the lab – it’s what happens after:
- Reduction in post-thrombotic syndrome
- Improvement in quality of life
- Decreased readmissions
- Shorter hospital stays and overall cost of care
As technology continues to evolve – from aspiration to more advanced thrombectomy approaches – we’re getting better at treating clot.
But as an industry, we need to continue shifting the conversation from procedural metrics to patient outcomes.
The next phase of VTE care won’t be defined by who has the newest device…
It will be defined by who can demonstrate meaningful, measurable impact on patients.”
Stay updated with Hemostasis Today.
-
Nov 2, 2026, 14:48Heghine Khachatryan: Vitamin B12 Replacement Choosing the Right Route for Each Patient
-
Nov 2, 2026, 14:28Anastasia Conti: ASH Global Research Award Backs New Directions in AML Research
-
Nov 2, 2026, 14:22Sara Zalghout: Linking Bacterial Virulence to NETosis and Thromboinflammation
-
Nov 2, 2026, 13:58Functional Iron Deficiency: From Iron Sequestration to Therapeutic Targeting
-
Nov 2, 2026, 13:56Jan Terje Andersen: Albumin Engineering Opens New Routes for Erythropoietin Delivery
-
Nov 2, 2026, 13:44Rishiraj Sinha: Strengthening ISBT–AABB Collaboration in Transfusion Medicine
-
Nov 2, 2026, 13:28Jeremiah Morris: Why Blood Detection Reagents Work Better on Dry Bloodstains
-
Nov 2, 2026, 12:38Maria Τektonidou: Machine Learning – A New Approach to CVD Risk in SLE
-
Nov 2, 2026, 12:31Toby Richards: Screening for Iron Deficiency – Nearly 1 in 4 Women Anaemic